Results 71 to 80 of about 31,390 (228)

Autoreactivity Versus Autoimmunity: Characteristics of Autoantigen‐Specific CD4 T Cells in Rheumatoid Arthritis and Health

open access: yesArthritis &Rheumatology, EarlyView.
Objective CD4 T cells specific for citrullinated (cit) peptides are key players in rheumatoid arthritis (RA) immunopathogenesis. Characterizing these cells and identifying features of healthy and RA‐associated autoreactivity will provide valuable insight into disease mechanisms and form the basis of immune state biomarkers to facilitate the next ...
James A. Stanway   +13 more
wiley   +1 more source

ENTPD1/CD39 is a promising therapeutic target in oncology [PDF]

open access: yesOncogene, 2012
Regulatory T cells (Tregs) are a subpopulation of CD4(+) T cells that are essential for maintaining the homeostasis of the immune system, limiting self-reactivity and excessive immune responses against foreign antigens. In cancer, infiltrated Tregs inhibit the effector lymphocytes and create a favorable environment for the growth of the tumor. Although
J, Bastid   +5 more
openaire   +2 more sources

Inhibitor selectivity using purified and membrane associated CD39. [PDF]

open access: yes, 2019
Inhibitors of CD39 and CD73 were incubated with purified CD39 (A, B) and Farage associated enzyme (C, D) and assayed for CD39 activity using ATP (A, C) or ADP (B, D) as substrate.
Said A. Goueli (7548320)   +1 more
core   +1 more source

CD38+CD39+ NK cells associate with HIV disease progression and negatively regulate T cell proliferation

open access: yesFrontiers in Immunology, 2022
The ectonucleotidases CD38 and CD39 have a critical regulatory effect on tumors and viral infections via the adenosine axis. Natural killer (NK) cells produce cytokines, induce cytotoxic responses against viral infection, and acquire immunoregulatory ...
Shi Qian   +21 more
doaj   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

open access: yesInternational Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg   +9 more
wiley   +1 more source

Expression of CD39 induced by in vitro transfection of HEK293 cells and ECs with the generated CD39 mRNA. [PDF]

open access: yes, 2015
Flow cytometric analyses of transfected HEK293 cells (A) human ECs (B) and immortalized porcine endothelial cells (PAE; C) with different CD39 mRNA concentrations. For control untreated and Lipofectamin-treated cells were used.
Andrea Nolte (797371)   +10 more
core   +1 more source

Glioma Stem Cells Upregulate CD39 Expression to Escape Immune Response through SOX2 Modulation [PDF]

open access: yes, 2022
Ectonucleotidase CD39 hydrolyzing extracellular ATP (eATP) functions as a key modulator of immune response in the tumor microenvironment, yet the role of CD39 in contributing tumor stem cells in a more immunosuppressive microenvironment remains elusive ...
Yanyan Li   +11 more
core   +1 more source

Electroacupuncture Alleviates Lung Injury in CpG1826-Challenged Mice via Modulating CD39-NLRP3 Pathway

open access: yesJournal of Inflammation Research, 2023
Jiasi Wu, Xin Xiong, Xiumin Hu Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, People’s Republic of ChinaCorrespondence: Jiasi Wu, Email wujiasi@cdutcm.edu.cnPurpose: Cytokine storm secondary lung ...
Wu J, Xiong X, Hu X
doaj  

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang   +10 more
wiley   +1 more source

Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis

open access: yesOncoImmunology, 2018
One of the mechanisms of tumor rejection in immune-modulatory treatments is antibody-dependent cell-mediated cytotoxicity (ADCC) of regulatory T cells (Tregs) that infiltrate tumors in which cells expressing activating Fcγ receptors (FcγRs) are present ...
Luigi Cari   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy